L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations

J. M. Cedarbaum, L. H. Toy, A. Green-Parsons

Research output: Contribution to journalArticlepeer-review

15 Scopus citations

Abstract

L-deprenyl (Eldepryl) added to Sinemet CR in the treatment regimens of seven patients with Parkinson's disease (PD) and therapeutic response fluctuations (RF) allowed a statistically significant reduction in total daily levodopa intake and an increase in the mean interdose interval. Trends were noted towards a reduction in the number of daily ''off'' periods and an increase in the portion of the waking day spent ''on.'' Three patients suffered an increase in the intensity of their dyskinesias, and discontinued taking deprenyl. Four patients, all of whom reported improved functioning during ''off'' periods, have continued taking the combination. Sinemet CR and deprenyl can safely be used together in patients with advanced PD, and the combination may result in improved control of motor fluctuations in selected patients.

Original languageEnglish
Pages (from-to)228-234
Number of pages7
JournalClinical Neuropharmacology
Volume14
Issue number3
DOIs
StatePublished - 1991
Externally publishedYes

Keywords

  • Controlled release
  • Deprenyl (selegiline)
  • Levodopa
  • Monoamine oxidase inhibitors
  • Parkinson's disease
  • Sustained release

Fingerprint

Dive into the research topics of 'L-deprenyl (selegiline) added to Sinemet CR in the management of Parkinson's disease patients with motor response fluctuations'. Together they form a unique fingerprint.

Cite this